

Synthesis of Teleocidins A, B and Their Congeners. Part 3.¹ Synthesis of Dihydroteleocidin B-4 (Dihydroteleocidin B), Teleocidin B-3 and Teleocidin B-4

Kazuaki Okabe, Hideaki Muratake, and Mitsutaka Natsume*


Research Foundation Itsuu Laboratory
 2-28-10 Tamagawa, Setagaya-ku, Tokyo 158, Japan

(Received in Japan 30 July 1991)

Key Words Alkaloid synthesis, Teleocidin B-3, Teleocidin B-4, Dihydroteleocidin B-4, Tumor promoter



Abstract — Details of the synthesis method of the tumor promoters teleocidin B-3 (3), teleocidin B-4 (4) and dihydroteleocidin B-4 (9) (=dihydroteleocidin B) from (S)- and (R)-methyl N-methyl-N-[7-(3,6,7-trimethyl-1,6-octadien-3-yl)-4-indolyl]-L-valinates (20b and 20a) are presented

Potent tumor promoters, teleocidins B-1 (1), B-2 (2), B-3 (3) and B-4 (4) are isolated from *Streptomyces medocidicus* together with teleocidins A-1 (5) and A-2 (6).² The teleocidin A family has a linallyl type of monoterpene side chain at the C-7 position of (–)-indolactam V (7),³ whereas the above four teleocidins B have an eleven carbon unit at the 6- and 7-positions of 7, constituting a six-membered ring and a variety of substituents such as the methyl, isopropyl and vinyl groups with a particular combination of stereochemical arrangement to form B-1 — B-4. In regard to this discrepancy, the extra one carbon atom in question was shown to have originated in L-methionine and a possible pathway through an intermediate 8 was discussed in the biogenesis of



1 Teleocidin B-1	vinyl	Me	1-Pr	Me
2 Teleocidin B-2	Me	vinyl	Me	1-Pr
3 Teleocidin B-3	Me	vinyl	1-Pr	Me
4 Teleocidin B-4	vinyl	Me	Me	1-Pr
9 Dihydro-teleocidin B-4	Et	Me	Me	1-Pr

5 Teleocidin A-1 =Lyngbyatoxin A	vinyl	Me
6 Teleocidin A-2	Me	vinyl



teleocidins B⁴ In the synthesis of these alkaloids, we had already made use of the chemical equivalent **10** of the cation **8** and succeeded in the total synthesis of dihydroteleocidin B-4 (**9**), teleocidin B-3 (**3**) and teleocidin B-4 (**4**), as reported in communications⁵ Here we describe the details of experiments, whose methodology is closely related to the preceding procedure of the teleocidin A synthesis¹ Total synthesis of racemic **3** and **4** has been reported by Nakatsuka and Goto⁶

Our plan for constructing the fundamental skeleton of the 6,7,8,9-tetrahydrobenz[*g*]indole ring system was to make an acid-catalyzed Friedel-Crafts type of intramolecular cyclization reaction on the compounds having the partial structure **10** So the preparation of indole derivatives **20** was required at first and this task was easily attained as shown in Chart 1, according to the established method described in the two preceding papers^{1,9} 3,6,7-Trimethyl-2,6-octadienyl bromide⁷ (**14**) was prepared from 5,6-dimethyl-5-hepten-2-one⁸ (**11**) in the following three steps in 29% yield i) the Horner-Emmons reaction of **11** with triethyl phosphonoacetate in the presence of sodium hydride, ii) reduction of the diene-ester **12** with lithium aluminum hydride and iii) bromination of the allyl alcohol **13** with carbon tetrabromide and triphenylphosphine Using this bromide **14**, the Grignard reaction was carried out with the *L*-valine derivative⁹ **15** in tetrahydrofuran at -20°C to furnish **16** in 70% yield. This was dehydrated with a catalytic amount of *p*-toluenesulfonic acid in refluxing benzene in 90% yield, and the resulting substance **17** was converted into the corresponding thioamide derivative **18** in 74% yield using the Lawesson's reagent¹⁰ in THF at reflux The indole formation from **18** was performed as before with iodomethane in dimethylformamide at room temperature⁹ to give **20a** and **20b** in 38% and 25% yields, respectively, accompanied by the formation of a by-product **19** in 30% yield




Chart 1

Table 1 Acid-Catalyzed Intramolecular Cyclization of Methyl *N*-Methyl-*N*-[7-[(*S*)-3,6,7-trimethyl-6-octen-3-yl]-4-indolyl]-*L*-valinate (21)

Acid (mol equiv.)	Solvent	Temperature (°C)	Time (h)	22a (%)	22b (%)	23a (%)	23b (%)	Recovery (%)
<i>p</i> -TsOH (15)	CHCl ₃	reflux	15	0	0	0	0	90
EtAlCl ₂ (12)	CH ₂ Cl ₂	-20 - -10	3	complex mixture				
BF ₃ ·OEt ₂ (40)	CH ₂ Cl ₂	0 - 20	7	33	19	26	17	0
SnCl ₄ (50)	CH ₂ Cl ₂	-20 - -10	1.5	36.5	13.5	14	7	0
conc H ₂ SO ₄ (30)	CH ₂ Cl ₂	0	4	40	10	15	8	0

Dihydroteleocidin B-4 (9) is a pure crystalline compound obtained accidentally by Takashima and Sakai during their structural investigation of the so-called "teleocidin B,"^{11a,11b} which is shown later to be a mixture of four components, teleocidins B-1 (1), B-2 (2), B-3 (3) and B-4 (4).² Fujiki and co-workers screened this dihydroteleocidin B-4 (9) (named "dihydroteleocidin B" at that time¹²) for the first time for tumor promoter activity¹³ and started the profound studies concerning the biological activities of this class of indole alkaloids.^{3a} To synthesize 9, the above indole derivative 20a was reduced catalytically over platinum oxide in methanol. Partial hydrogenation proceeded without trouble and dihydro compound 21 was obtained in 92% yield. The intramolecular cyclization of 21 was then studied using both protomic and the Lewis acids as shown in Table 1. The acids such as *p*-toluenesulfonic acid, trifluoromethanesulfonic acid and dichloroethylaluminum afforded only disappointing results, but boron trifluoride etherate and tin(IV) chloride produced the desired cyclized





Chart 2

Table 2 Acid-Catalyzed Intramolecular Cyclization of Methyl (*R*)- and (*S*)-*N*-Methyl-*N*-[7-(3,6,7-trimethyl-1,6-octadien-3-yl)-4-indolyl]-L-valinates (**20a** and **20b**)



Substrate	Acid (mol equiv)	Solvent	Temperature (°C)	Time	Product (Yield %)
20b	conc H_2SO_4 (63)	CH_2Cl_2	-60	1 h	complex mixture
20b	SnCl_4 (35)	CH_2Cl_2	-40	14 min	complex mixture
20a	$\text{BF}_3 \cdot \text{OEt}_2$ (43.5)	CH_2Cl_2	0 \rightarrow r t	5.5 h	30a + 31a (17) (10.1)
20a	$\text{BF}_3 \cdot \text{OEt}_2$ (40)	$\text{ClCH}_2\text{CH}_2\text{Cl}$	0 \rightarrow r t	7.5 h	30a (20)
20b	$\text{BF}_3 \cdot \text{OEt}_2$ (17)	$\text{ClCH}_2\text{CH}_2\text{Cl}$	0 \rightarrow r t	7 h	31b (14)

compounds as two diastereoisomers **22a** and **22b**, where the compound **22a** having the bulky alkyl substituents, *i.e.*, the ethyl and isopropyl groups, at the *trans* situation was formed in a predominant amount. Other tricyclic derivatives **23a** and **23b** were obtained as unwanted by-products. The stereochemical arrangement of **22a** and **22b** was uncertain at this stage, and the successful total synthesis of **9** from **22a** revealed this as shown. Concentrated sulfuric acid gave the best yield of the required compound **22a** for further synthesis.

Treatment of product **22a** with ethyl 3-bromo-2-hydroxyiminopropanoate in the presence of sodium carbonate¹⁴ provided **24**, **25** and **26** in 57%, 2.5% and 9% yields, respectively (Chart 2). The oxime compound **24** was reduced with aluminum-amalgam to give amino-diester **27a** and **27b** in 40% and 39.5% yields. Separation of these two diastereomers at this stage made it easy to purify the final products. The amino-diester **27a** was then treated with sodium borohydride in the presence of lithium chloride¹⁵ to give the amino-alcohol **28a**, which was submitted to the next step without further purification, since the chromatography on either silica gel or alumina caused a great loss of the material. The last intramolecular amide formation was carried out in the same manner as described in the preceding paper¹ using diphenylphosphoryl azide¹⁶ (DPPA) to afford dihydroteleocidin B-4 (**9**) in 18% yield, calculated from **27a**. The synthetic material **9** was identified as authentic dihydroteleocidin B-4 by comparing their mp, MS, IR, ¹H NMR and CD spectra as well as their biological activity. In a similar way, the amino-diester **27b** was converted into 9-epidihydroteleocidin B-4 (**29**) via the amino-alcohol **28b** in 13% yield.

Contrary to the satisfactory formation of the cyclized compounds **22** having the 6,7,8,9-tetrahydrobenz[g]-indole ring system from the dihydro derivative **21**, acid treatment of vinyl compounds **20** gave a rather disappointing result. Treatment of **20a** or **20b** with a number of protonic and Lewis acids such as trifluoroacetic acid, trifluoromethanesulfonic acid, tetrafluoroboric acid-diethyl ether complex, concentrated sulfuric acid, boron trichloride, magnesium bromide diethyl etherate, aluminum trichloride, tin(IV) chloride, titanium(IV) chloride, and antimony trichloride gave no definite product, or the recovery of **20**. Boron trifluoride etherate was the only reagent which gave a positive result (Table 2), producing the desired compounds **30** and **31** in low yields. It is significant that the high selectivity to yield only **30a** or **31b**, bearing the *trans* relationship between vinyl and isopropyl groups, was done by using 1,2-dichloroethane as a solvent. The rest of the product obtained

in a major amount was an inseparable complex mixture of various type of isomers originating from the acid-catalyzed cyclization reaction of the terpenic side chain. So we decided to carry out the six-membered ring cyclization at the final stage of the synthesis by knowing Koshimizu and co-workers' successful conversion of blastmycetm D into olhovretm A.^{4,17}

25-Methylteleocidins A-1 (35a A) and A-2 (35b A) were prepared from 20a and 20b by way of 32a and 32b, 33a and 33b, and 34a and 34b, according to our established procedure (Chart 3).¹ During introduction of the side chain at the C-3 position of 20a and 20b, formation of the by-products 37a and 37b, 38a and 38b, and




Chart 3

39a and **39b** was unavoidable as observed in the former cases¹. In view of the poor yield at the cyclization step to dihydroteleocidin B-4 (**9**), diethylphosphoryl cyanide (DEPC)¹⁸ was used for the lactam ring formation to yield **35a A** + **36a A** (*ca* 8:1) (33%) and **35a B** + **36a B** (28%) from **34a**, and **35b A** + **36b A** (*ca* 8:1) (32%) and **35b B** + **36b B** (28%) from **34b**. The undesired compounds **36a A** and **36b A** were contaminated in 25-methylteleocidins A-1 (**35a A**) and A-2 (**35b A**) due to partial racemization of the L-valine portion during alkaline hydrolysis¹. To protect the hydroxyl group, **35a A** + **36a A** and **35b A** + **36b A** were acetylated with acetic anhydride in pyridine to get **40a** + **41a** and **40b** + **41b** in quantitative and 97% yields, and these were subjected to the intramolecular Friedel-Crafts type of cyclization catalyzed with boron trifluoride etherate in 1,2-dichloroethane. Compared with the preliminary reaction on **20**, a little improvement of yields was observed here, and the desired compounds **42a** + **43a** and **42b** + **43b** were obtained in 25% and 24% yields, respectively. The acetyl group of **42a** + **43a** and **42b** + **43b** was removed by alkaline hydrolysis and the resulting mixtures of alcohols were separated by HPLC to afford teleocidin B-4 (**4**) and the enantiomer of teleocidin B-3 (**44a**) in 72% and 7% yields, as well as teleocidin B-3 (**3**) and the enantiomer of teleocidin B-4 (**44b**) in 70.5% and 9% yields. The synthetic teleocidins B-3 (**3**) and B-4 (**4**) proved to be identical with the natural specimens by comparing the mp, MS, IR, ¹H NMR and CD spectra as well as their biological activities. Structural support of **44a** (= ent-**3**) and **44b** (= ent-**4**) was obtained by the antipodal CD curves, together with the identical MS and ¹H NMR spectra in comparison with those of **3** and **4**.

EXPERIMENTAL

General Procedures — Details were described in the two preceding papers¹⁹.

3,6,7-Trimethyl-2,6-octadienyl Bromide (14) — To a suspension of 50% NaH (5.7 g, 0.12 mol) in dry benzene (60 ml) was added triethyl phosphonoacetate (26.7 g, 0.12 mol) at room temperature to keep the internal temperature below 35°C under Ar atmosphere. The mixture was stirred at room temperature for 1 h and then cooled to 0°C. 5,6-Dimethyl-5-hepten-2-one (15.0 g, 0.11 mol) in dry benzene (15 ml) was added dropwise and stirring was continued under Ar atmosphere at 0°C — room temperature for 14 h. The mixture was poured into NH₄Cl-H₂O, the whole was extracted with Et₂O, and the organic layer was worked up as usual. Distillation (95–110°C/4 mmHg) afforded crude ethyl 3,6,7-trimethyl-2,6-octadienoate (**12**) (21.5 g), which contained impurity originating from triethyl phosphonoacetate. To a solution of the crude diene-ester **12** (21.5 g) in THF (200 ml) was added portionwise LiAlH₄ (3.0 g, 0.08 mol) at 0°C and the mixture was stirred at that temperature for 30 min. It was quenched with sat. Rochell salt-H₂O, the whole was extracted with Et₂O, and the organic layer was worked up as usual. Distillation gave 3,6,7-trimethyl-2,6-octadien-1-ol (**13**), bp 110–116°C/8 mmHg (10.1 g, 56%) as colorless oil. IR (film) cm⁻¹: 3350, 1667. ¹H NMR (90 MHz) δ: 4.15 (2H, d, J=7 Hz), 5.42 (1H, t, J=7 Hz). To a cooled solution (0°C) of the above alcohol **13** (15.9 g, 0.095 mol) and Ph₃P (26.0 g, 0.10 mol) in CH₃CN (100 ml) was added portionwise CBr₄ (32.9 g, 0.10 mol), and the solution was stirred at 0°C for 3 h. It was extracted with n-hexane and the hexane solution was rinsed several times with a small amount of CH₃CN to remove CHBr₃ completely. Evaporation of hexane and purification by distillation gave the bromide **14**, bp 86–99°C/4 mmHg (11.1 g, 51%) as colorless oil. IR (film) cm⁻¹: 1658. ¹H NMR (90 MHz) δ: 1.66 (9H, s), 1.75 (3H, s), 2.00–2.20 (4H, m), 4.00 (2H, d, J=9 Hz), 5.52 (1H, t, J=9 Hz).

Methyl N-[4-Hydroxy-4-(2-pyrrolyl)-5,8,9-trimethyl-5-vinyl-8-decenoyl]-N-methyl-L-valinate (16) — In a similar manner as reported previously,¹⁹ L-valine derivative **15** (198 mg, 0.44 mmol) was treated with the above bromide **14** (412 mg, 1.78 mmol) and Mg (85 mg, 3.50 mmol) in THF (8 ml) at 0°C for 3 h to give **16** (118 mg) and *N*-tosylate of **16** (32 mg). The latter was reduced with Mg (29 mg) in MeOH (2 ml) to afford the additional **16** (19 mg), totaling 137 mg (70%) of **16**, colorless syrup. MS *m/z*: 428 (M⁺-H₂O). IR (CHCl₃) cm⁻¹: 1735, 1618. ¹H NMR (90 MHz) δ: 2.80 and 2.83 (3H, s each), 3.62 and 3.66 (3H, s each), 3.80 and 4.90 (1H, d each, J=10.5 Hz), 4.21 (1H, s, OH), 5.04 (1H, d, J=18 Hz), 5.33 (1H, d, J=12 Hz), 6.04 (1H, dd, J=18, 12 Hz), 6.05–6.23 (1H, m), 6.56–6.72 (1H, m), 8.81 (1H, br s).

Methyl N-Methyl-N-[4-(2-pyrrolyl)-5,8,9-trimethyl-5-vinyl-3,8-decadienoyl]-L-valinate (17) — In a

similar manner as reported previously,¹⁹ the above compound **16** (132 mg, 0.30 mmol) was dehydrated with *p*-TsOH·H₂O (10 mg, 0.05 mmol) in refluxing benzene (5 ml) for 2 min to afford **17** (114 mg, 90%) as colorless syrup. HRMS Calcd for C₂₆H₄₀N₂O₃ 428.3039 Found. 428.3049. IR (CHCl₃) cm⁻¹ 1738, 1625. ¹H NMR (90 MHz) δ 0.82, 0.84 and 1.00 (6H, d each, J=7 Hz), 1.21 (3H, s), 1.51 (6H, s), 1.57 (3H, s), 2.87 and 2.91 (3H, s each), 3.04-3.25 (2H, m), 3.70 (3H, s), 3.92 and 4.92 (1H, d each, J=10.5 Hz), 5.67 (1H, t, J=7.5 Hz), 5.95-6.21 (2H, m), 6.57-6.76 (1H, m), 9.50 and 9.54 (1H, br s each).

Methyl N-Methyl-N-[4-(2-pyrrolyl)-5,8,9-trimethyl-5-vinyl-3,8-decadienyl]-L-valinate (18) — In a similar manner as reported previously,¹⁹ the above amide **17** (61.5 mg, 0.14 mmol) was heated with Lawesson's reagent (58 mg, 0.14 mmol) in THF (3 ml) at 85°C for 1 h to afford **18** (47 mg, 74%) as colorless syrup, accompanied by the recovery of **17** (3 mg, 5%). HRMS Calcd for C₂₆H₄₀N₂O₂S 444.2810 Found. 444.2812. IR (CHCl₃) cm⁻¹ 1738. ¹H NMR (90 MHz) δ 0.73, 0.83, 0.84 and 1.08 (6H, d each, J=7 Hz), 1.53 (6H, s), 1.58 (3H, s), 3.05 and 3.31 (3H, s each), 3.44-3.63 (2H, m), 3.67 and 3.71 (3H, s each), 4.27 and 6.30 (1H, d each, J=10.5 Hz), 5.05 (1H, dd, J=18, 1 Hz), 5.10 (1H, dd, J=11, 1 Hz), 5.70 and 5.73 (1H, t each, J=7 Hz), 5.90-6.21 (2H, m), 6.57-6.75 (1H, m), 8.92 (1H, br s).

Methyl N-Methyl-N-[7-[(R)-3,6,7-trimethyl-1,6-octadien-3-yl]-4-indolyl]-L-valinate (20a) and **Methyl N-Methyl-N-[7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]-4-indolyl]-L-valinate (20b)** — In a similar manner as reported previously,¹⁹ the thioamide compound **18** (48 mg, 0.11 mmol) was treated with MeI (0.5 ml, 8.03 mmol) in DMF (1 ml) at 19°C for 4 h to yield **20a** (17 mg, 38%) and **20b** (11 mg, 25%) together with 4-(methylthio)-7-(3,6,7-trimethyl-1,6-octadien-3-yl)indole (**19**) (10 mg, 30%). **20a** Colorless syrup. HRMS Calcd for C₂₆H₃₈N₂O₂ 410.2933 Found 410.2936 [α]_D²⁴ -140.9° (c 1.248, CH₂Cl₂). IR (CHCl₃) cm⁻¹ 1728. ¹H NMR (90 MHz) δ 0.93 (3H, d, J=7 Hz), 1.10 (3H, d, J=7 Hz), 1.40 (3H, s), 1.46 (3H, s), 1.56 (6H, s), 2.37 (1H, dq, J=10.5, 7, 7 Hz), 2.99 (3H, s), 3.57 (3H, s), 4.09 (1H, d, J=10.5 Hz), 5.24 (1H, dd, J=10.5, 1 Hz), 5.26 (1H, dd, J=18, 1 Hz), 6.26 (1H, dd, J=18, 10.5 Hz), 6.60 (1H, d, J=8 Hz), 6.68 (1H, dd, J=3, 2 Hz), 7.00 (1H, d, J=8 Hz), 7.06 (1H, dd, J=3, 3 Hz), 8.62 (1H, br s). **20b** Colorless scales, mp 68-70°C (MeOH-H₂O). Anal. Calcd for C₂₆H₃₈N₂O₂ C, 76.05, H, 9.32, N, 6.82. Found C, 75.96, H, 9.32, N, 6.80. [α]_D²² -180.1° (c 0.784, CH₂Cl₂). IR (KBr) cm⁻¹ 1718. ¹H NMR (90 MHz) δ 0.91 (3H, d, J=7 Hz), 1.01 (3H, d, J=7 Hz), 1.38 (3H, s), 1.44 (3H, s), 1.55 (6H, s), 2.37 (1H, dq, J=10.5, 7, 7 Hz), 3.03 (3H, s), 3.33 (3H, s), 4.10 (1H, d, J=10.5 Hz), 5.24 (1H, dd, J=10.5, 1 Hz), 5.25 (1H, dd, J=18, 1 Hz), 6.24 (1H, dd, J=18, 10.5 Hz), 6.56 (1H, d, J=8 Hz), 6.70 (1H, dd, J=3, 2 Hz), 7.00 (1H, d, J=8 Hz), 7.04 (1H, dd, J=3, 3 Hz), 8.59 (1H, br s). **19** Colorless syrup. HRMS Calcd for C₂₀H₂₇NS 313.1864 Found 313.1868. ¹H NMR (90 MHz) δ 1.42 (3H, s), 1.48 (3H, s), 1.57 (6H, s), 2.54 (3H, s), 5.26 (1H, dd, J=10.5, 1 Hz), 5.26 (1H, dd, J=18, 1 Hz), 6.24 (1H, dd, J=18, 10.5 Hz), 6.62 (1H, dd, J=3, 2 Hz), 6.98 (1H, d, J=8 Hz), 7.11 (1H, d, J=8 Hz), 7.13 (1H, dd, J=3, 3 Hz), 8.65 (1H, br s).

Methyl N-Methyl-N-[7-[(S)-3,6,7-trimethyl-6-octen-3-yl]-4-indolyl]-L-valinate (21) — A solution of **20a** (324 mg, 0.79 mmol) in MeOH (25 ml) was stirred in the presence of PtO₂ (45 mg) under an ordinary atmosphere of H₂ at 25°C for 3 h. The mixture was filtered on a celite bed, the celite was washed with CH₂Cl₂ and the combined organic layer was evaporated *in vacuo*. The residue was purified by PTLC [hexane-EtOAc (20/1)] to give **21** (300 mg, 92%) as colorless syrup. HRMS Calcd for C₂₆H₄₀N₂O₂ 412.3089 Found 412.3106. IR (CHCl₃) cm⁻¹ 1725. ¹H NMR (90 MHz) δ 0.66 (3H, t, J=7 Hz), 0.92 (3H, d, J=7 Hz), 1.08 (3H, d, J=7 Hz), 1.30 (3H, s), 1.42 (3H, s), 1.46 (3H, s), 1.54 (3H, s), 2.38 (1H, dq, J=10.5, 7, 7 Hz), 2.99 (3H, s), 3.56 (3H, s), 4.06 (1H, d, J=10.5 Hz), 6.54 (1H, d, J=8 Hz), 6.69 (1H, dd, J=3, 2 Hz), 6.88 (1H, d, J=8 Hz), 7.07 (1H, dd, J=3, 3 Hz), 8.32 (1H, br s).

Methyl N-[(6R, 9S)-6,9-Dimethyl-9-ethyl-6-(1-methylethyl)-6,7,8,9-tetrahydro-1H-benz[*g*]indol-4-yl]-N-methyl-L-valinate (22a) and **Methyl N-[(6S, 9S)-6,9-Dimethyl-9-ethyl-6-(1-methylethyl)-6,7,8,9-tetrahydro-1H-benz[*g*]indol-4-yl]-N-methyl-L-valinate (22b)** — To a solution of **21** (24 mg, 0.06 mmol) in CH₂Cl₂ (7.5 ml) was added 95% H₂SO₄ (0.1 ml, 30 equiv.) at 0°C and the mixture was stirred at 0°C for 4 h. Sat. NaHCO₃-H₂O was added, the whole was extracted with CH₂Cl₂ and worked up as usual. The residue was separated by PTLC [hexane-EtOAc (15/1)] to afford **23a** + **23b** (5.5 mg) and **22a** + **22b** (12.5 mg). The former mixture was further separated by PTLC [hexane-EtOAc (30/1)] to give **Methyl N-[(4S, 7S)-4,7-Dimethyl-7-ethyl-4-(1-methylethyl)-4,5,6,7-tetrahydro-azepino[3,2,*l*-*hi*]indol-10-yl]-N-methyl-L-valinates (23a)** (3.5

mg, 15%) and (23b) (2 mg, 8%) The latter mixture was further separated by PTLC [hexane-DME (49 1)] and purified by recrystallization to furnish 22a (9.5 mg, 40%) and 22b (2.5 mg, 10%). 22a Colorless needles, mp 134–136°C (MeOH-H₂O) Anal. Calcd for C₂₆H₄₀N₂O₂ C, 75.68, H, 9.77, N, 6.79. Found C, 75.65, H, 9.60, N, 6.57 HRMS Calcd for C₂₆H₄₀N₂O₂ 412.3089 Found 412.3093. [α]_D²⁴ -102.0° (c 0.495, CH₂Cl₂). IR (KBr) cm⁻¹ 1720 ¹H NMR (90 MHz) δ 0.52 (3H, d, J=7 Hz), 0.54 (3H, t, J=7 Hz), 0.84 (3H, d, J=7 Hz), 0.99 (3H, d, J=7 Hz), 1.11 (3H, d, J=7 Hz), 1.33 (3H, s), 1.40 (3H, s), 2.97 (3H, s), 3.54 (3H, s), 4.01 (1H, d, J=10.5 Hz), 6.57 (1H, s), 6.64 (1H, dd, J=3, 2 Hz), 7.03 (1H, dd, J=3, 3 Hz), 8.28 (1H, br s) 22b: Colorless prisms, mp 195–196°C (MeOH) Anal. Calcd for C₂₆H₄₀N₂O₂ C, 75.68, H, 9.77; N, 6.79 Found. C, 75.42; H, 9.59; N, 6.71 HRMS Calcd for C₂₆H₄₀N₂O₂ 412.3089 Found 412.3086 [α]_D²⁴ -178.6° (c 0.500, CH₂Cl₂) IR (KBr) cm⁻¹ 1735 ¹H NMR (90 MHz) δ. 0.58 (3H, d, J=7 Hz), 0.86 (3H, t, J=7 Hz), 0.95 (6H, d, J=7 Hz), 1.13 (3H, d, J=7 Hz), 1.28 (3H, s), 1.41 (3H, s), 2.94 (3H, s), 3.57 (3H, s), 3.98 (1H, d, J=10.5 Hz), 6.50–6.67 (1H, m), 6.58 (1H, s), 7.05 (1H, dd, J=3, 3 Hz), 8.21 (1H, br s) 23a Colorless prisms, mp 100–101°C (CH₂Cl₂-MeOH) Anal. Calcd for C₂₆H₄₀N₂O₂ C, 75.68, H, 9.77, N, 6.79 Found C, 75.75, H, 9.80, N, 6.83 IR (KBr) cm⁻¹ 1740, 1730 ¹H NMR (90 MHz) δ 0.28 (3H, d, J=7 Hz), 0.43 (3H, t, J=7 Hz), 0.71 (3H, d, J=7 Hz), 0.83 (3H, d, J=7 Hz), 1.06 (3H, d, J=7 Hz), 1.44 (3H, s), 1.65 (3H, s), 2.97 (3H, s), 3.56 (3H, s), 3.98 (1H, d, J=10.5 Hz), 6.59 (1H, d, J=8 Hz), 6.67 (1H, d, J=3 Hz), 6.85 (1H, d, J=8 Hz), 7.16 (1H, d, J=3 Hz) 23b Colorless syrup HRMS Calcd for C₂₆H₄₀N₂O₂ 412.3089 Found 412.3078 IR (CHCl₃) cm⁻¹ 1710 ¹H NMR (90 MHz) δ 0.40 (3H, d, J=7 Hz), 0.81 (3H, d, J=7 Hz), 0.91 (3H, d, J=7 Hz), 0.95 (3H, t, J=7 Hz), 1.10 (3H, d, J=7 Hz), 1.18 (3H, s), 1.61 (3H, s), 3.00 (3H, s), 3.62 (3H, s), 3.82 (1H, d, J=10.5 Hz), 6.64 (1H, d, J=8 Hz), 6.67 (1H, d, J=3 Hz), 6.96 (1H, d, J=8 Hz), 7.11 (1H, d, J=3 Hz)

Ethyl (6*R*, 9*S*)-6,9-Dimethyl-9-ethyl-α-(hydroxyimino)-4-[[*(S)*-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-6-(1-methylethyl)-6,7,8,9-tetrahydro-1*H*-benz[*g*]indole-3-propanoate (24) — In the same manner as in the preceding paper,¹ 22a (100 mg, 0.24 mmol) was converted into 24 (75 mg, 57%), 25 (4 mg, 2.5%) and 26 (14 mg, 9%), accompanied by the recovery of 22a (11 mg, 11%) 24 Colorless syrup MS m/z 541 (M⁺) IR (CHCl₃) cm⁻¹ 1725 ¹H NMR (90 MHz) δ 0.43 (3H, d, J=7 Hz), 0.50 (3H, t, J=7 Hz), 0.91 (3H, d, J=7 Hz), 0.94 (3H, d, J=7 Hz), 1.15 (3H, d, J=7 Hz), 1.20 (3H, t, J=7 Hz), 1.30 (3H, s), 1.37 (3H, s), 2.90 (3H, s), 3.47 (3H, s), 3.62 (1H, d, J=10 Hz), 4.22 (2H, q, J=7 Hz), 4.32 (1H, d, J=15 Hz), 4.54 (1H, d, J=15 Hz), 6.69 (1H, d, J=3 Hz), 6.84 (1H, s), 8.06 (1H, br s), 10.23 (1H, br s, OH) **Diethyl (6*R*, 9*S*)-α, α'-Bis(hydroxyimino)-6,9-dimethyl-9-ethyl-4-[[*(S)*-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-6-(1-methylethyl)-6,7,8,9-tetrahydro-1*H*-benz[*g*]indole-2,3-bispropanoate (25)** Colorless film IR (CHCl₃) cm⁻¹ 1732 ¹H NMR (90 MHz) δ 2.88 (3H, s), 3.43 (3H, s), 3.51 (1H, d, J=10.5 Hz), 3.97 (2H, q, J=7 Hz), 4.00 (2H, s), 4.29 (2H, q, J=7 Hz), 4.54 (2H, s), 6.78 (1H, s), 8.93 (1H, br s), 10.08 (2H, br s, OH) **Ethyl (1*S*, 4*R*)-1,4-Dimethyl-8-(ethoxycarbonyl)-1-ethyl-1,2,3,4,10a,11-hexahydro-α-(hydroxyimino)-6-[[*(S)*-1-(methoxycarbonyl)-2-methylpropyl]methylamino]benz[*g*][1,2]oxazino[6,5-*b*]indole-6*b*(7*H*)-propanoate (26)** Colorless film MS m/z 670 (M⁺) IR (CHCl₃) cm⁻¹ 1732, 1725 ¹H NMR (90 MHz) δ 2.67 and 2.80 (3H, s each), 3.55 (3H, s), 4.71–4.98 (1H, m, NH), 5.13–5.44 (1H, m), 6.48–6.65 (1H, m), 9.43 (1H, br s, OH)

Ethyl (α*S*, 6*R*, 9*S*)-α-Amino-6,9-dimethyl-9-ethyl-4-[[*(S)*-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-6-(1-methylethyl)-6,7,8,9-tetrahydro-1*H*-benz[*g*]indole-3-propanoate (27a) and Ethyl (α*R*, 6*R*, 9*S*)-α-Amino-6,9-dimethyl-9-ethyl-4-[[*(S)*-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-6-(1-methylethyl)-6,7,8,9-tetrahydro-1*H*-benz[*g*]indole-3-propanoate (27b) — According to the same procedure as in the preceding paper,¹ 24 (74 mg, 0.14 mmol) was reduced to 27a (29 mg, 40%) and 27b (28.5 mg, 39.5%) after separation by PTLC [hexane-EtOAc (1 4)] 27a Colorless syrup MS m/z 527 (M⁺) IR (CHCl₃) cm⁻¹ 1730 ¹H NMR (90 MHz) δ 0.40 (3H, d, J=7 Hz), 0.50 (3H, t, J=7 Hz), 0.92 (3H, d, J=7 Hz), 0.96 (3H, d, J=7 Hz), 1.13 (3H, d, J=7 Hz), 1.22 (3H, t, J=7 Hz), 1.31 (3H, s), 1.38 (3H, s), 2.83 (3H, s), 3.38 (3H, s), 3.58 (1H, d, J=8 Hz), 4.13 (2H, q, J=7 Hz), 6.77 (1H, s), 6.93 (1H, d, J=2 Hz), 8.20 (1H, br s) 27b Colorless syrup MS m/z 527 (M⁺) IR (CHCl₃) cm⁻¹ 1730 ¹H NMR (90 MHz) δ. 0.40 (3H, d, J=7 Hz), 0.50 (3H, t, J=7 Hz), 0.94 (6H, d, J=7 Hz), 1.06 (3H, t, J=7 Hz), 1.13 (3H, d, J=7 Hz), 1.30 (3H, s), 1.38 (3H, s), 2.82 (3H, s), 3.37 (3H, s), 3.60 (1H, d, J=8 Hz), 4.04 (2H, q, J=7 Hz), 6.77 (1H, s), 6.92 (1H, d, J=2 Hz), 8.20 (1H, br s)

Dihydroteleocidin B-4 (Dihydroteleocidin B) (9) — The amino-diester 27a (13 mg, 0.025 mmol) was

reduced to the amino-alcohol **28a** with NaBH_4 (19 mg, 0.50 mmol) and LiCl (21 mg, 0.50 mmol) in EtOH-THF (4:3) (2.8 ml) at room temperature. In the same manner as in the teleocidin A synthesis,¹ **28a** was converted into dihydroteleocidin B-4 (**9**) (2 mg, 18% from **27a**) as colorless prisms, mp 154–156°C and 232–235°C (decomp) (acetone- H_2O) [lit.^{11a} mp 154–156°C and 223–224.5°C (decomp), lit.^{11c} mp 168°C and 233–235°C (decomp)]. No mp depression was observed when admixed with the authentic dihydroteleocidin B-4. HRMS Calcd for $\text{C}_{28}\text{H}_{43}\text{N}_3\text{O}_2$ 453.3355. Found 453.3358. CD (c 2.23 $\times 10^{-5}$, MeOH, 21°C) $[\theta]_{327}^0$, $[\theta]_{310}^0$ +4400, $[\theta]_{297}^0$, $[\theta]_{262}^0$ -13000, $[\theta]_{240}^0$ -12400, $[\theta]_{225}^0$ -22600, $[\theta]_{215}^0$. IR (KBr) cm^{-1} 1632. $^1\text{H NMR}$ (400 MHz, $\text{CDCl}_3\text{-D}_2\text{O}$) δ : (major conformer) 0.50 (3H, d, $J=7$ Hz), 0.60 (3H, t, $J=7$ Hz), 0.70 (3H, d, $J=7$ Hz), 0.92 (3H, d, $J=7$ Hz), 0.99 (3H, d, $J=7$ Hz), 1.32 (3H, s), 1.39 (3H, s), 2.63 (1H, dq, $J=10.5, 7, 7$ Hz), 2.91 (3H, s), 2.94 (1H, dd, $J=16, 4$ Hz), 3.17 (1H, br d, $J=16$ Hz), 3.51 (1H, dd, $J=11, 9$ Hz), 3.74 (1H, dd, $J=11, 4$ Hz), 4.28–4.37 (1H, m), 4.31 (1H, d, $J=10.5$ Hz), 6.53 (1H, s), 6.84 (1H, s), 8.14 (1H, br s), (minor conformer) 0.53 (3H, d, $J=7$ Hz), 0.60 (3H, t, $J=7$ Hz), 0.94 (3H, d, $J=7$ Hz), 1.00 (3H, d, $J=7$ Hz), 1.25 (3H, d, $J=7$ Hz), 1.35 (3H, s), 1.40 (3H, s), 2.37 (1H, dq, $J=10.5, 7, 7$ Hz), 2.69 (1H, d, $J=10.5$ Hz), 2.73 (3H, s), 2.77 (1H, dd, $J=14, 1$ Hz), 3.05 (1H, dd, $J=14, 5$ Hz), 3.44 (1H, dd, $J=11, 8$ Hz), 3.53 (1H, dd, $J=11, 6$ Hz), 4.39–4.46 (1H, m), 6.92 (1H, d, $J=2$ Hz), 7.00 (1H, s), 8.30 (1H, br s).

9-Epidihydroteleocidin B-4 (29) — In the same procedure as above, **29** was obtained in 13% yield from **27b** by way of the amino-alcohol **28b**. **29** Colorless prisms, mp 259–261°C (acetone- H_2O). HRMS Calcd for $\text{C}_{28}\text{H}_{43}\text{N}_3\text{O}_2$ 453.3355. Found 453.3349. IR (KBr) cm^{-1} 1662. $^1\text{H NMR}$ (400 MHz, $\text{CDCl}_3\text{-D}_2\text{O}$) δ : (major conformer) 0.53 (3H, d, $J=7$ Hz), 0.57 (3H, t, $J=7$ Hz), 0.76 (3H, d, $J=7$ Hz), 0.83 (3H, d, $J=7$ Hz), 1.03 (3H, d, $J=7$ Hz), 1.26 (3H, s), 1.38 (3H, s), 2.65 (1H, dq, $J=10.5, 7, 7$ Hz), 2.89 (1H, br d, $J=15$ Hz), 3.08 (3H, s), 3.25 (1H, br d, $J=15$ Hz), 3.88 (1H, d, $J=10.5$ Hz), (minor conformer) 0.51 (3H, d, $J=7$ Hz), 0.59 (3H, t, $J=7$ Hz), 0.95 (3H, d, $J=7$ Hz), 0.99 (3H, d, $J=7$ Hz), 1.24 (3H, d, $J=7$ Hz), 2.34 (1H, dq, $J=10.5, 7, 7$ Hz), 2.70 (3H, s), 2.76 (1H, d, $J=13$ Hz), 2.91 (1H, d, $J=10.5$ Hz), 3.02 (1H, d, $J=13$ Hz).

$\text{BF}_3 \cdot \text{OEt}_2$ -Catalyzed Intramolecular Cyclization of 20b — To a solution of **20b** (99 mg, 0.24 mmol) in 1,2-dichloroethane (12 ml) was added $\text{BF}_3 \cdot \text{OEt}_2$ (0.5 ml, 4.07 mmol) at 0°C, and the mixture was stirred at 0°C for 2.5 h and then at room temperature for 4.5 h. Sat. $\text{NaHCO}_3\text{-H}_2\text{O}$ was added, the whole was extracted with CH_2Cl_2 and worked up as usual to give a residue (103.5 mg). This was separated by PTLC [hexane-EtOAc (34:1)] and purified by recrystallization to afford methyl *N*-[(6*S*, 9*S*)-6,9-dimethyl-9-vinyl-6-(1-methylethyl)-6,7,8,9-tetrahydro-1*H*-benz[*g*]indol-4-yl]-*N*-methyl-L-valinate (**31b**) (14 mg, 14%), mp 135–137°C (MeOH- H_2O), as colorless prisms. Anal. Calcd for $\text{C}_{26}\text{H}_{38}\text{N}_2\text{O}_2$: C, 76.05; H, 9.32; N, 6.82. Found: C, 76.12; H, 9.39; N, 6.87. IR (KBr) cm^{-1} 1725. $^1\text{H NMR}$ (400 MHz) δ : 0.57 (3H, d, $J=7$ Hz), 0.97 (3H, d, $J=7$ Hz), 1.00 (3H, d, $J=7$ Hz), 1.14 (3H, d, $J=7$ Hz), 1.32 (3H, s), 1.38–1.52 (2H, m), 1.49 (3H, s), 1.85–1.97 (2H, m), 2.24 (1H, dq, $J=7, 7$ Hz), 2.37 (1H, dq, $J=11, 7, 7$ Hz), 2.94 (3H, s), 3.59 (3H, s), 4.02 (1H, d, $J=11$ Hz), 5.23 (1H, dd, $J=11, 1$ Hz), 5.39 (1H, dd, $J=18, 1$ Hz), 6.18 (1H, dd, $J=18, 11$ Hz), 6.56 (1H, dd, $J=3, 2$ Hz), 6.58 (1H, s), 7.01 (1H, dd, $J=3, 3$ Hz), 8.64 (1H, br s).

Reaction of 20a and 20b with Ethyl 3-Bromo-2-hydroxyiminopropanoate — In the same manner as in the preceding paper,¹ **20a** (97 mg, 0.24 mmol) in CH_2Cl_2 (6 ml) was stirred with ethyl 3-bromo-2-hydroxyiminopropanoate (50 mg, 0.24 mmol) and Na_2CO_3 (50 mg, 0.47 mmol) at 20°C for 16.5 h to afford **32a** (72.5 mg, 57%), **37a** (28 mg, 22%), **38a** (11 mg, 7%) and **39a** (10.5 mg, 7%). Similarly **20b** (103 mg, 0.25 mmol) was converted into **32b** (83 mg, 61%), **37b** (22 mg, 16%), **38b** (8 mg, 5%) and **39b** (8 mg, 5%). **Ethyl α -(Hydroxyimino)-4-[(*S*)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(*R*)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-3-propanoate (**32a**)** Colorless syrup. MS m/z 539 (M^+). IR (CHCl_3) cm^{-1} 1730. $^1\text{H NMR}$ (90 MHz) δ : 0.93 (3H, d, $J=7$ Hz), 1.13 (3H, d, $J=7$ Hz), 1.21 (3H, t, $J=7.5$ Hz), 1.36 (3H, s), 1.45 (3H, s), 1.56 (6H, s), 2.92 (3H, s), 3.53 (3H, s), 3.66 (1H, d, $J=9$ Hz), 4.20 (2H, q, $J=7.5$ Hz), 4.35 (1H, d, $J=15$ Hz), 4.57 (1H, d, $J=15$ Hz), 5.20 (1H, dd, $J=10.5, 1$ Hz), 5.22 (1H, dd, $J=18, 1$ Hz), 6.18 (1H, dd, $J=18, 10.5$ Hz), 6.69 (1H, d, $J=3$ Hz), 6.83 (1H, d, $J=8$ Hz), 6.97 (1H, d, $J=8$ Hz), 8.40 (1H, br s), 10.26 (1H, br s, OH). **Ethyl α -(Hydroxyimino)-4-[(*S*)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(*R*)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-5-propanoate (**37a**)** Colorless syrup. MS m/z 539 (M^+). IR (CHCl_3) cm^{-1} 1730, 1725. $^1\text{H NMR}$ (90 MHz) δ : 0.92 (3H, d, $J=7$ Hz), 1.20 (3H, t, $J=7.5$ Hz), 1.22 (3H, d, $J=7$ Hz), 1.30 (3H, s), 1.43 (3H, s), 1.54 (6H, s), 3.07 (3H, s), 3.20–3.61 (1H, m), 3.43 (3H, s), 4.15 (2H, q, $J=7.5$ Hz), 4.41 (1H, d, $J=15$ Hz), 5.20

(1H, dd, J=10.5, 1.5 Hz), 5.21 (1H, dd, J=18, 1.5 Hz), 6.21 (1H, dd, J=18, 10.5 Hz), 6.44 (1H, dd, J=3, 2 Hz), 6.80 (1H, s), 6.96 (1H, dd, J=3, 3 Hz), 8.47 (1H, br s), 9.75 (1H, br s, OH). **Diethyl α, α' -Bis(hydroxyimino)-4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(R)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-3,5-bispropanoate (38a)** Colorless film MS m/z 668 (M^+) IR (CHCl₃) cm⁻¹ 1725 ¹H NMR (90 MHz) δ 0.70 (3H, d, J=7 Hz), 0.95 (3H, d, J=7 Hz), 1.25 (6H, t, J=7.5 Hz), 1.26 (6H, s), 1.38 (3H, s), 1.54 (3H, s), 2.97 (3H, s), 3.76 (3H, s), 4.11 (2H, q, J=7.5 Hz), 4.12 (2H, q, J=7.5 Hz), 4.45 (1H, d, J=15 Hz), 4.80 (1H, d, J=15 Hz), 5.17 (1H, d, J=10.5 Hz), 5.20 (1H, d, J=18 Hz), 6.17 (1H, dd, J=18, 10.5 Hz), 6.51-6.71 (1H, m), 6.58 (1H, s), 8.26 (1H, br s), 9.27 (2H, br s, OH) **Ethyl 9,9a-Dihydro-3-(ethoxycarbonyl)- α -(hydroxyimino)-5-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(R)-3,6,7-trimethyl-1,6-octadien-3-yl]-1,2-oxazino[6,5-b]indole-4a(4H)-propanoate (39a)**. Colorless film MS m/z 668 (M^+) IR (CHCl₃) cm⁻¹ 1730 ¹H NMR (90 MHz) δ 0.93 (3H, d, J=7 Hz), 2.69 and 2.82 (3H, s each), 3.53 (3H, s), 5.99 (1H, dd, J=18, 10.5 Hz), 6.51 and 6.53 (1H, d each, J=8 Hz), 6.95 (1H, d, J=8 Hz), 9.18 (1H, br s, OH). **Ethyl α -(Hydroxyimino)-4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-3-propanoate (32b)** Colorless syrup MS m/z 539 (M^+) IR (CHCl₃) cm⁻¹ 1723 ¹H NMR (90 MHz) δ 0.93 (3H, d, J=7 Hz), 1.09 (3H, d, J=7 Hz), 1.19 (3H, t, J=7.5 Hz), 1.37 (3H, s), 1.45 (3H, s), 1.55 (6H, s), 2.89 (3H, s), 3.58 (3H, s), 3.67 (1H, d, J=8 Hz), 4.21 (2H, q, J=7 Hz), 4.36 (1H, d, J=15 Hz), 4.54 (1H, d, J=15 Hz), 5.21 (1H, d, J=10.5 Hz), 5.22 (1H, d, J=17.5 Hz), 6.18 (1H, dd, J=17.5, 10.5 Hz), 6.69 (1H, br d, J=1.5 Hz), 6.85 (1H, d, J=7.5 Hz), 6.98 (1H, d, J=7.5 Hz), 8.40 (1H, br s), 10.20 (1H, br s, OH) **Ethyl α -(Hydroxyimino)-4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-5-propanoate (37b)** Colorless syrup MS m/z 539 (M^+) IR (CHCl₃) cm⁻¹ 1718 ¹H NMR (90 MHz) δ 0.87 (3H, d, J=7 Hz), 1.20 (3H, d, J=7 Hz), 1.20 (3H, t, J=7 Hz), 1.28 (3H, s), 1.38 (3H, s), 1.44 (3H, s), 1.52 (3H, s), 3.07 (3H, s), 3.23-3.50 (1H, m), 3.37 (3H, s), 4.10 (1H, d, J=15 Hz), 4.19 (2H, q, J=7 Hz), 4.44 (1H, d, J=15 Hz), 5.19 (1H, d, J=10.5 Hz), 5.21 (1H, d, J=17.5 Hz), 6.19 (1H, dd, J=17.5, 10.5 Hz), 6.44 (1H, dd, J=3, 2 Hz), 6.81 (1H, s), 6.98 (1H, dd, J=3, 3 Hz), 8.46 (1H, br s), 9.71 (1H, br s, OH) **Diethyl α, α' -Bis(hydroxyimino)-4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]indole-3,5-bispropanoate (38b)** Colorless film MS m/z 668 (M^+) IR (CHCl₃) cm⁻¹ 1722 ¹H NMR (90 MHz) δ 0.73 (3H, d, J=7 Hz), 0.97 (3H, d, J=7 Hz), 1.40 (3H, s), 1.52 (3H, s), 1.54 (3H, s), 2.94 and 3.00 (3H, s each), 3.55 and 3.76 (3H, s each), 5.18 (1H, d, J=10.5 Hz), 5.20 (1H, d, J=18 Hz), 6.16 (1H, dd, J=18, 10.5 Hz), 6.57 and 6.70 (1H, s each), 6.62 (1H, d, J=3 Hz), 8.26 (1H, br s), 9.26 (2H, br s, OH) **Ethyl 9,9a-Dihydro-3-(ethoxycarbonyl)- α -(hydroxyimino)-5-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]-1,2-oxazino[6,5-b]indole-4a(4H)-propanoate (39b)** Colorless film MS m/z 668 (M^+) IR (CHCl₃) cm⁻¹ 1720 ¹H NMR (90 MHz) δ 0.94 and 0.96 (3H, d each, J=7 Hz), 2.68 and 2.76 (3H, s each), 3.59 and 3.64 (3H, s each), 5.91 and 5.95 (1H, dd each, J=18, 10.5 Hz), 6.48 and 6.52 (1H, d each, J=7.5 Hz), 6.96 (1H, d, J=7.5 Hz), 9.33 (1H, br s, OH)

Reduction of 32a and 32b with Al-Hg — According to the procedure reported in the preceding paper,¹ the oxime derivative **32a** (55 mg, 0.10 mmol) was reduced with Al-Hg [prepared from Al (83 mg, 3.07 mmol)] in THF-H₂O (9/1) (6 ml) under Ar atmosphere at 40°C for 1 h to afford **33a** (46.5 mg, 87%). A similar treatment of **32b** (65 mg, 0.12 mmol) gave **33b** (57 mg, 90%). **Ethyl 4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(R)-3,6,7-trimethyl-1,6-octadien-3-yl]tryptophanate (33a)** Colorless syrup MS m/z 525 (M^+) IR (CHCl₃) cm⁻¹ 1728 ¹H NMR (90 MHz) of two diastereoisomers (*ca* 1/1) δ 0.94 (3H, d, J=7 Hz), 1.14 (3H, t, J=7.5 Hz), 1.16 and 1.20 (3H, d each, J=7 Hz), 1.36 (3H, s), 1.47 (3H, s), 2.87 (3H, s), 2.98 (1H, dd, J=14, 9 Hz), 3.43 (3H, s), 4.08 and 4.15 (2H, q each, J=7.5 Hz), 5.22 (1H, d, J=10.5 Hz), 5.22 (1H, d, J=18 Hz), 6.22 (1H, dd, J=18, 10.5 Hz), 6.80 (1H, d, J=8 Hz), 6.95 (1H, d, J=8 Hz), 8.50 (1H, br s) **Ethyl 4-[(S)-1-(methoxycarbonyl)-2-methylpropyl]methylamino]-7-[(S)-3,6,7-trimethyl-1,6-octadien-3-yl]tryptophanate (33b)** Colorless syrup MS m/z 525 (M^+) IR (CHCl₃) cm⁻¹ 1725 ¹H NMR (90 MHz) of two diastereoisomers (*ca* 1/1) δ 0.95 (3H, d, J=7 Hz), 1.08 and 1.10 (3H, d each, J=7 Hz), 1.15 and 1.17 (3H, t each, J=7 Hz), 1.31 (3H, s), 1.35 (3H, s), 1.44 (3H, s), 1.54 (3H, s), 1.70 (2H, s, NH₂), 2.11-2.54 (1H, m), 2.83 (3H, s), 2.97 (1H, dd, J=15, 9 Hz), 3.45 (3H, s), 3.64 (1H, d, J=7 Hz), 4.09 and 4.15 (2H, q each, J=7 Hz), 5.22 (1H, dd, J=10.5, 1.5 Hz), 5.22 (1H, dd, J=18, 1.5 Hz), 6.18 (1H, dd, J=18, 10.5 Hz), 6.81 (1H, d, J=7.5 Hz), 6.90-

6 98 (1H, br s), 6 96 (1H, d, $J=7.5$ Hz), 8 50 (1H, br s)

Methyl *N*-[3-(2-Amino-3-hydroxypropyl)-7-[(*R*)-3,6,7-trimethyl-1,6-octadien-3-yl]-4-indolyl]-*N*-methyl-*L*-valinate (34a) and Methyl *N*-[3-(2-Amino-3-hydroxypropyl)-7-[(*S*)-3,6,7-trimethyl-1,6-octadien-3-yl]-4-indolyl]-*N*-methyl-*L*-valinate (34b) — In a similar manner as in the preceding paper,¹ reduction of **33a** (46 mg, 0.088 mmol) with NaBH₄ (66 mg, 1.75 mmol) was carried out in the presence of LiCl (74 mg, 1.75 mmol) in EtOH-THF (4:3) (6.3 ml) under Ar atmosphere at 20°C for 12 h to give **34a** (33 mg, 78%) Similarly **34b** (27 mg, 84%) was prepared from **33b** (35 mg, 0.067 mmol) **34a**: Colorless syrup MS *m/z* 483 (M⁺) IR (CHCl₃) cm⁻¹ 1725 ¹H NMR (90 MHz) of two diastereoisomers (*ca* 1:1) δ 0.88 (3H, d, $J=7$ Hz), 1.10 and 1.13 (3H, d each, $J=7$ Hz), 1.32 (3H, s), 1.44 (3H, s), 2.71 (3H, s, NH₂ and OH), 2.80 and 2.82 (3H, s each), 3.39 and 3.43 (3H, s each), 5.23 (1H, d, $J=10.5$ Hz), 5.24 (1H, d, $J=18$ Hz), 6.20 (1H, dd, $J=18, 10.5$ Hz), 6.77 (1H, d, $J=8$ Hz), 6.80-6.97 (1H, m), 6.95 (1H, d, $J=8$ Hz), 8.50 (1H, br s). **34b** Colorless syrup MS *m/z* 483 (M⁺) IR (CHCl₃) cm⁻¹ 1727 ¹H NMR (90 MHz) of two diastereoisomers (*ca* 1:1) δ 0.93 (3H, d, $J=7$ Hz), 1.09 and 1.12 (3H, d each, $J=7$ Hz), 1.26 (3H, s), 1.33 (3H, s), 1.46 (3H, s), 1.55 (3H, s), 2.36-2.59 (3H, m, NH₂ and OH), 2.81 and 2.83 (3H, s each), 3.44 and 3.46 (3H, s each), 3.68 (1H, d, $J=7$ Hz), 5.23 (1H, dd, $J=18, 1.5$ Hz), 5.24 (1H, dd, $J=10, 1.5$ Hz), 6.19 (1H, dd, $J=18, 10$ Hz), 6.78 (1H, d, $J=8$ Hz), 6.88-6.97 (1H, m), 6.95 (1H, d, $J=8$ Hz), 8.50 (1H, br s)

(*R*)-7-(3,6,7-Trimethyl-1,6-octadien-3-yl)-(-)-indolactam V (25-Methylteleocidin A-1) (35a A) and (*R*)-7-(3,6,7-Trimethyl-1,6-octadien-3-yl)-9-epi-(-)-indolactam V (35a B) — The same procedure using DEPC (diethylphosphoryl cyanide) as in the preceding paper¹ was applied to the amino-alcohol **34a** (45.5 mg, 0.094 mmol) to give **35a A** containing **36a A** (**35a A** **36a A** = *ca* 8:1) (14 mg, 33%) and **35a B** containing **36a B** (10.5 mg, 28%) **35a A** with a contaminant **36a A** Colorless syrup MS *m/z* 451 (M⁺) IR (CHCl₃) cm⁻¹ 1658 ¹H NMR (400 MHz, CDCl₃-D₂O) of **35a A** δ (major conformer) 0.65 (3H, d, $J=7$ Hz), 0.92 (3H, d, $J=7$ Hz), 1.47 (3H, s), 1.48 (3H, s), 1.59 (3H, s), 1.60 (3H, s), 2.59 (1H, dq, $J=10.5, 7, 7$ Hz), 2.91 (3H, s), 3.02 (1H, dd, $J=17.5, 3$ Hz), 3.15 (1H, d, $J=17.5$ Hz), 3.55 (1H, dd, $J=11, 8$ Hz), 3.73 (1H, dd, $J=11, 3$ Hz), 4.27-4.38 (1H, m), 4.34 (1H, d, $J=10.5$ Hz), 5.30 (1H, d, $J=11$ Hz), 5.31 (1H, d, $J=18$ Hz), 6.17 (1H, dd, $J=18, 11$ Hz), 6.48 (1H, d, $J=8$ Hz), 6.82 (1H, s), 7.00 (1H, d, $J=8$ Hz), 8.52 (1H, br s), (minor conformer) 0.94 (3H, d, $J=7$ Hz), 1.25 (3H, d, $J=7$ Hz), 1.50 (3H, s), 1.58 (3H, s), 2.39 (1H, dq, $J=10.5, 7, 7$ Hz), 2.73 (3H, s), 2.81 (1H, dd, $J=15, 1$ Hz), 3.07 (1H, dd, $J=15, 4$ Hz), 3.39 (1H, dd, $J=11, 7$ Hz), 3.46 (1H, dd, $J=11, 7$ Hz), 4.38-4.47 (1H, m), 5.34 (1H, d, $J=11$ Hz), 5.35 (1H, d, $J=18$ Hz), 6.23 (1H, dd, $J=18, 11$ Hz), 6.95 (1H, s), 7.01 (1H, d, $J=8$ Hz), 7.11 (1H, d, $J=8$ Hz), 8.76 (1H, br s) ¹H NMR (400 MHz, CDCl₃-D₂O) of **36a A** δ (major conformer) 0.58 (3H, d, $J=7$ Hz), 2.91 (3H, s), 8.55 (1H, br s), (minor conformer) 2.74 (3H, s) The ratio between **35a A** and **36a A** was estimated from the integrated values of the signals at 0.65 (d) and 0.58 (d) of each major conformer **35a B** with a contaminant **36a B** Colorless syrup MS *m/z* 451 (M⁺) IR (CHCl₃) cm⁻¹ 1658 ¹H NMR (400 MHz, CDCl₃-D₂O) of **35a B** δ (major conformer) 0.71 (3H, d, $J=7$ Hz), 0.75 (3H, d, $J=7$ Hz), 1.47 (3H, s), 1.48 (3H, s), 1.57 (3H, s), 1.60 (3H, s), 2.61 (1H, dq, $J=10.5, 7, 7$ Hz), 2.91 (1H, d, $J=16$ Hz), 3.09 (3H, s), 3.25 (1H, d, $J=16$ Hz), 3.91 (1H, d, $J=10.5$ Hz), 5.28 (1H, d, $J=10.5$ Hz), 5.30 (1H, d, $J=18$ Hz), 6.16 (1H, dd, $J=18, 10.5$ Hz), 6.73 (1H, d, $J=8$ Hz), 6.81 (1H, s), 6.97 (1H, d, $J=8$ Hz), 8.44 (1H, br s), (minor conformer) 0.65 (3H, d, $J=7$ Hz), 0.95 (3H, d, $J=7$ Hz), 2.37 (1H, dq, $J=10.5, 7, 7$ Hz), 2.71 (3H, s), 2.78 (1H, d, $J=14$ Hz), 6.22 (1H, dd, $J=18, 10.5$ Hz), 7.00 (1H, s), 7.01 (1H, d, $J=8$ Hz), 7.12 (1H, d, $J=8$ Hz) ¹H NMR (400 MHz, CDCl₃-D₂O) of **36a B** δ (major conformer) 0.65 (3H, d, $J=7$ Hz), 6.96 (1H, d, $J=8$ Hz)

(*S*)-7-(3,6,7-Trimethyl-1,6-octadien-3-yl)-(-)-indolactam V (25-Methylteleocidin A-2) (35b A) and (*S*)-7-(3,6,7-Trimethyl-1,6-octadien-3-yl)-9-epi-(-)-indolactam V (35b B) — The same procedure using DEPC (diethylphosphoryl cyanide) as in the preceding paper¹ was applied to the amino-alcohol **34b** (46.5 mg, 0.096 mmol) to give **35b A** containing **36b A** (**35b A** **36b A** = *ca* 8:1) (14 mg, 32%) and **35b B** containing **36b B** (12 mg, 28%) **35b A** with a contaminant **36b A** Colorless syrup MS *m/z* 451 (M⁺) IR (CHCl₃) cm⁻¹ 1657 ¹H NMR (400 MHz, CDCl₃-D₂O) of **35b A** δ (major conformer) 0.58 (3H, d, $J=7$ Hz), 0.90 (3H, d, $J=7$ Hz), 1.32 (3H, s), 1.45 (3H, s), 1.52 (3H, s), 1.56 (3H, s), 2.56 (1H, dq, $J=10.5, 7, 7$ Hz), 2.89 (3H, s), 3.06 (1H, dd, $J=15, 3$ Hz), 3.14 (1H, d, $J=15$ Hz), 3.57 (1H, dd, $J=11.5, 8$ Hz), 3.72 (1H, dd, $J=11.5, 3$ Hz), 4.28-4.40 (1H, m), 4.35 (1H, d, $J=10.5$ Hz), 5.26 (1H, d, $J=11$ Hz), 5.30 (1H, d, $J=18$ Hz), 6.22 (1H, dd, $J=18, 11$ Hz), 6.47 (1H, d, $J=8$

H_z, 6 82 (1H, s), 6 97 (1H, d, J=8 Hz), 8 54 (1H, br s), (minor conformer) 0 93 (3H, d, J=7 Hz), 1 25 (3H, d, J=7 Hz), 2 37 (1H, dq, J=10.5, 7, 7 Hz), 2 74 (3H, s), 2 82 (1H, dd, J=15, 1 Hz), 2 99 (1H, d, J=10 5 Hz), 3 33 (1H, dd, J=11, 7 5 Hz), 3 41 (1H, dd, J=11, 7 Hz), 4 40-4 47 (1H, m), 5 32 (1H, d, J=11 Hz), 5 33 (1H, d, J=18 Hz), 6 17 (1H, dd, J=18, 11 Hz), 7 01 (1H, d, J=8 Hz), 7 11 (1H, d, J=8 Hz), 8 77 (1H, br s) ¹H NMR (400 MHz, CDCl₃-D₂O) of **36b A** δ (major conformer) 0 65 (3H, d, J=7 Hz), 2 91 (3H, s), 7 00 (1H, d, J=8 Hz), (minor conformer) 2 72 (3H, s) The ratio between **35b A** and **36b A** was estimated from the integrated values of the signals at 0 58 (d) and 0 65 (d) of each major conformer **35b B** with a contaminant **36b B** Colorless syrup MS m/z 451 (M⁺) IR (CHCl₃) cm⁻¹ 1655 ¹H NMR (400 MHz, CDCl₃-D₂O) of **35b B** δ (major conformer) 0 66 (3H, d, J=7 Hz), 0 73 (3H, d, J=7 Hz), 1 33 (3H, s), 1 44 (3H, s), 1 53 (3H, s), 1 57 (3H, s), 2 59 (1H, dq, J=10 5, 7, 7 Hz), 2 89 (1H, dd, J=16, 2 Hz), 3 09 (3H, s), 3 26 (1H, dd, J=16, 2 Hz), 3 91 (1H, d, J=10 5 Hz), 5 27 (1H, dd, J=11, 1 Hz), 5 29 (1H, dd, J=18, 1 Hz), 6 23 (1H, dd, J=18, 11 Hz), 6 73 (1H, d, J=8 Hz), 6 81 (1H, d, J=2 Hz), 6 96 (1H, d, J=8 Hz), 8 45 (1H, br s), (minor conformer) 0 95 (3H, d, J=7 Hz), 2 35 (1H, dq, J=10 5, 7, 7 Hz), 2 73 (3H, s), 2 78 (1H, d, J=14 Hz), 3 02 (1H, d, J=10 5 Hz), 6 16 (1H, dd, J=18, 11 Hz), 7 01 (1H, d, J=8 Hz), 7 12 (1H, d, J=8 Hz), 8 72 (1H, br s) ¹H NMR (400 MHz, CDCl₃-D₂O) of **36b B** δ (major conformer) 0 77 (3H, d, J=7 Hz), 6 73 (1H, d, J=8 Hz), 6 97 (1H, d, J=8 Hz), 8 44 (1H, br s)

(*R*)-14*O*-Acetyl-7-(3,6,7-trimethyl-1,6-octadien-3-yl)-(-)-indolactam **V** (**40a**) and (*S*)-14*O*-Acetyl-7-(3,6,7-trimethyl-1,6-octadien-3-yl)-(-)-indolactam **V** (**40b**) — To a solution of **35a A** + **36a A** (114 5 mg, 0 254 mmol) in pyridine (1 5 ml) and CH₂Cl₂ (1 ml) was added Ac₂O (0 75 ml, 7 96 mmol) at 0°C, and the mixture was stirred at 0°C for 1 h The solvent was evaporated, sat NaHCO₃-H₂O was added and the whole was extracted with CH₂Cl₂ Usual work-up and PTLC [hexane-EtOAc (2 1)] afforded **40a** with a contaminant **41a** (125 mg, 100%) Similarly **35b A** + **36b A** (128 mg) gave **40b** with a contaminant **41b** (135 5 mg, 97%) **40a** with **41a** Colorless syrup MS m/z 493 (M⁺) IR (CHCl₃) cm⁻¹ 1740, 1658 ¹H NMR (90 MHz) δ 0 94 (3H, d, J=7 Hz), 2 02 and 2 10 (3H, s each), 2 74 and 2 98 (3H, s each), 6 16 and 6 23 (1H, dd, J=18, 10 5 Hz), 6 47 (1H, d, J=8 Hz), 6 80 and 6 87 (1H, d each, J=2 Hz), 8 51 and 8 72 (1H, br s each) **40b** with **41b** Colorless syrup MS m/z 493 (M⁺) IR (CHCl₃) cm⁻¹ 1737, 1652 ¹H NMR (90 MHz) δ 0 92 and 0 93 (3H, d each, J=7 Hz), 2 03 and 2 09 (3H, s each), 2 74 and 2 92 (3H, s each), 6 22 (1H, dd, J=18, 10 5 Hz), 6 47 (1H, d, J=8 Hz), 8 53 and 8 72 (1H, br s each).

14*O*-Acetylteleocidin **B-4** (**42a**) and 14*O*-Acetylteleocidin **B-3** (**42b**) — To a solution of **40a** + **41a** (125 mg, 0 254 mmol) in 1,2-dichloroethane (37 5 ml) was added BF₃·OEt₂ (1 25 ml, 10 2 mmol) at 0°C and the mixture was stirred at 0°C for 1 h Sat NaHCO₃-H₂O was added, the whole was extracted with CH₂Cl₂ and worked up as usual PTLC [hexane-CHCl₃-i-PrOH (86 10 4)] of the residue afforded the crude products (33 5 mg), which was purified by PTLC [hexane-EtOAc (2 1)] to give **42a** containing a contaminant **43a** (31 5 mg, 25%) Similarly **42b** with a contaminant **43b** (31 mg, 24%) was obtained from **40b** + **41b** (130 mg) **42a** with **43a** Colorless syrup MS m/z 493 (M⁺) IR (CHCl₃) cm⁻¹ 1735, 1653 ¹H NMR (90 MHz) (two conformers) δ 0 55, 0 62, 0 70, 0 94 and 1 01 (Me protons of the two i-Pr groups, d each, J=7 Hz), 1 35 (3H, s), 1 51 (3H, s), 1 91 and 2 08 (3H, s each), 2 73 and 2 92 (3H, s each), 5 22 (1H, d, J=10 5 Hz), 5 35 (1H, d, J=18 Hz), 6 14 and 6 17 (1H, dd each, J=18, 10 5 Hz), 6 50 and 6 99 (1H, s each), 6 74 and 6 79 (1H, d each, J=3 Hz), 8 68 and 8 73 (1H, br s each) **42b** with **43b** Colorless syrup MS m/z 493 (M⁺) IR (CHCl₃) cm⁻¹ 1740, 1655, 1652 ¹H NMR (90 MHz) (two conformers) δ 0 58, 0 66, 0 92 and 1 03 (Me protons of the two i-Pr groups, d each, J=7 Hz), 1 31 1 33 (3H, s each), 1 46 and 1 51 (3H, s each), 2 04 and 2 08 (3H, s each), 2 74 and 2 91 (3H, s each), 6 20 (1H, dd, J=18, 10 5 Hz), 6 47 and 7 00 (1H, s each), 8 64 and 8 77 (1H, br s each)

Teleocidin **B-4** (**4**) — A solution of **42a** + **43a** (34 mg, 0 069 mmol) in MeOH (5 ml) was stirred with K₂CO₃ (48 mg, 0 35 mmol) at 0°C for 40 min Sat NH₄Cl-H₂O was added, the whole was extracted with CH₂Cl₂ and worked up as usual to give a residue (36 5 mg), which was separated by HPLC [column YMC A-324, ODS, S-5, 10 × 300 mm, mobile phase MeOH-H₂O-CHCl₃ (78 20 2), flow rate 2 ml/min] to afford **4** (25 5 mg, retention time 130 8 min) and **44a** (3 5 mg, retention time 120 4 min) The former compound was further purified by PTLC [hexane-EtOAc (1 1)] and recrystallization from CH₂Cl₂-i-Pr₂O to give teleocidin **B-4** (**4**) (22 5 mg, 72%), colorless prisms, mp 233-235°C (lit^{3b} mp 230-232 5°C) No depression of mp was observed on admixture with the authentic sample of **4** Similarly ent-teleocidin **B-3** (**44a**) (2 5 mg, 8%) was obtained The

synthetic 4 HRMS Calcd for $C_{28}H_{41}N_3O_2$: 451.3198. Found. 451.3212. CD ($c 2.26 \times 10^{-5}$, MeOH, 21°C): $[\theta]_{327} 0$, $[\theta]_{311} +4000$, $[\theta]_{302} 0$, $[\theta]_{260} -24500$, $[\theta]_{255} -23300$, $[\theta]_{252} -24000$, $[\theta]_{249} -23500$, $[\theta]_{240} -37000$, $[\theta]_{235} -30500$, $[\theta]_{225} -50500$, $[\theta]_{210} 0$. IR (KBr) cm^{-1} : 1640. 1H NMR (400 MHz, $CDCl_3$ - D_2O) δ : (major conformer) 0.53 (3H, d, $J=7$ Hz), 0.69 (3H, d, $J=7$ Hz), 0.91 (3H, d, $J=7$ Hz), 1.01 (3H, d, $J=7$ Hz), 1.35 (3H, s), 1.51 (3H, s), 2.25 (1H, qq, $J=7, 7$ Hz), 2.61 (1H, dq, $J=10.5, 7, 7$ Hz), 2.91 (3H, s), 2.97 (1H, dd, $J=17.5, 4$ Hz), 3.12 (1H, d, $J=17.5$ Hz), 3.51 (1H, dd, $J=11, 9$ Hz), 3.71 (1H, dd, $J=11, 4$ Hz), 4.27-4.36 (1H, m), 4.31 (1H, d, $J=10.5$ Hz), 5.25 (1H, dd, $J=10.5, 1$ Hz), 5.41 (1H, dd, $J=18, 1$ Hz), 6.16 (1H, dd, $J=18, 10.5$ Hz), 6.51 (1H, s), 6.76-6.80 (1H, m), 8.68 (1H, br s), (minor conformer) 0.61 (3H, d, $J=7$ Hz), 0.93 (3H, d, $J=7$ Hz), 1.03 (3H, d, $J=7$ Hz), 1.24 (3H, d, $J=7$ Hz), 1.50 (3H, s), 2.37 (1H, dq, $J=10.5, 7, 7$ Hz), 2.73 (3H, s), 2.74 (1H, dd, $J=15, 1$ Hz), 2.85 (1H, d, $J=10.5$ Hz), 3.03 (1H, dd, $J=15, 5$ Hz), 3.42 (1H, dd, $J=11, 7$ Hz), 4.38-4.46 (1H, m), 5.28 (1H, d, $J=10.5$ Hz), 5.42 (1H, d, $J=18$ Hz), 6.21 (1H, dd, $J=18, 10.5$ Hz), 6.87 (1H, d, $J=2$ Hz), 7.02 (1H, s), 8.77 (1H, br s). Ent-teleocidin B-3 (44a). Colorless prisms, mp 155-158°C (CH_2Cl_2 -i-Pr $_2O$). HRMS Calcd for $C_{28}H_{41}N_3O_2$: 451.3198. Found: 451.3192. CD ($c 2.33 \times 10^{-5}$, MeOH, 21°C) $[\theta]_{322} 0$, $[\theta]_{302} -6500$, $[\theta]_{294} 0$, $[\theta]_{262} +18000$, $[\theta]_{258} +16000$, $[\theta]_{253} +19500$, $[\theta]_{247} +17500$, $[\theta]_{240} +24000$, $[\theta]_{236} +18000$, $[\theta]_{223} +27500$, $[\theta]_{214} 0$. 1H NMR spectrum (400 MHz) was identical with that of teleocidin B-3 (3) described below.

Teleocidin B-3 (3) — The same treatment as above yielded teleocidin B-3 (3) (20 mg, 70%) and ent-teleocidin B-4 (44b) (2.5 mg, 9%) from 42b + 43b (31 mg). The synthetic 3: Colorless prisms, mp 155-158°C (CH_2Cl_2 -i-Pr $_2O$) (lit.^{3b} mp 160-162°C). No depression of mp was observed on admixture with the authentic sample of 3. HRMS Calcd for $C_{28}H_{41}N_3O_2$: 451.3198. Found. 451.3210. CD ($c 2.26 \times 10^{-5}$, MeOH, 21°C) $[\theta]_{323} 0$, $[\theta]_{307} +7500$, $[\theta]_{294} 0$, $[\theta]_{258} -20000$, $[\theta]_{247} -19000$, $[\theta]_{240} -27000$, $[\theta]_{235} -19000$, $[\theta]_{225} -30000$, $[\theta]_{212} 0$. IR (KBr) cm^{-1} : 1638. 1H NMR (400 MHz, $CDCl_3$ - D_2O) δ : (major conformer) 0.62 (3H, d, $J=7$ Hz), 0.64 (3H, d, $J=7$ Hz), 0.91 (3H, d, $J=7$ Hz), 1.01 (3H, d, $J=7$ Hz), 1.30 (3H, s), 1.46 (3H, s), 2.27 (1H, qq, $J=7, 7$ Hz), 2.60 (1H, dq, $J=10.5, 7, 7$ Hz), 2.89 (3H, s), 2.93 (1H, dd, $J=18.5, 4$ Hz), 3.13 (1H, d, $J=18.5$ Hz), 3.51 (1H, dd, $J=11, 9$ Hz), 3.75 (1H, dd, $J=11, 4$ Hz), 4.28 (1H, d, $J=10.5$ Hz), 4.28-4.36 (1H, m), 5.24 (1H, dd, $J=10.5, 1$ Hz), 5.37 (1H, dd, $J=18, 1$ Hz), 6.22 (1H, dd, $J=18, 10.5$ Hz), 6.47 (1H, s), 6.76 (1H, s), 8.46 (1H, br s); (minor conformer) 0.58 (3H, d, $J=7$ Hz), 0.93 (3H, d, $J=7$ Hz), 1.02 (3H, d, $J=7$ Hz), 1.24 (3H, d, $J=7$ Hz), 1.33 (3H, s), 1.50 (3H, s), 2.24 (1H, qq, $J=7, 7$ Hz), 2.38 (1H, dq, $J=11.5, 7, 7$ Hz), 2.73 (3H, s), 2.78 (1H, dd, $J=15, 1$ Hz), 2.91 (1H, d, $J=11.5$ Hz), 3.05 (1H, dd, $J=15, 5$ Hz), 3.45 (1H, dd, $J=11.5, 7.5$ Hz), 3.50 (1H, dd, $J=11.5, 6$ Hz), 4.36-4.46 (1H, m), 5.30 (1H, d, $J=10.5$ Hz), 5.44 (1H, d, $J=18$ Hz), 6.19 (1H, dd, $J=18, 10.5$ Hz), 6.89 (1H, d, $J=3$ Hz), 7.03 (1H, s), 8.79 (1H, br s). Ent-teleocidin B-4 (44b): Colorless prisms, mp 231-234°C (CH_2Cl_2 -i-Pr $_2O$). HRMS Calcd for $C_{28}H_{41}N_3O_2$: 451.3198. Found 451.3187. CD ($c 2.00 \times 10^{-5}$, MeOH, 21°C) $[\theta]_{322} 0$, $[\theta]_{314} -2500$, $[\theta]_{302} 0$, $[\theta]_{255} +19000$, $[\theta]_{248} +17500$, $[\theta]_{240} +28000$, $[\theta]_{235} +23000$, $[\theta]_{224} +37000$, $[\theta]_{210} 0$. 1H NMR spectrum (400 MHz) was identical with that of teleocidin B-4 (4) described above.

ACKNOWLEDGMENT

Authors' heartiest thanks are due to Professor Shin-ichiro Sakai of Chiba University for his generous gift of precious samples of dihydroteleocidin B-4, teleocidin B-3 and teleocidin B-4. We also thank Dr. Hirota Fujiki of National Cancer Center Research Institute for assay of the biological activities. This work was supported by a Grant-in-Aid from the Ministry of Education, Science and Culture, which is gratefully acknowledged.

REFERENCES AND NOTES

- 1 Part 2: Muratake, H., Okabe, K.; Natsume, M. *Tetrahedron* preceding paper
- 2 (a) Sakai, S.; Aimi, N.; Yamaguchi, K.; Hitotsuyanagi, Y.; Watanabe, C.; Yokose, K.; Koyama, Y.; Shudo, K.; Itai, A. *Chem Pharm Bull* 1984, 32, 354-357. (b) Hitotsuyanagi, Y.; Fujiki, H.; Saganuma, M.; Aimi, N.; Sakai, S.; Endo, Y.; Shudo, K.; Sugimura, T. *Chem. Pharm Bull* 1984, 32, 4233-4236
- 3 (a) Fujiki, H.; Sugimura, T. *Cancer Surveys* 1983, 2, 539-556. (b) Sakai, S.; Hitotsuyanagi, Y.; Aimi, N.; Fujiki, H.; Saganuma, M.; Sugimura, T.; Endo, Y.; Shudo, K. *Tetrahedron Lett* 1986, 27, 5219-5220.

- 4 Irie, K.; Kajiyama, S.; Funaki, A.; Koshimizu, K., Hayashi, H.; Arai, M. *Tetrahedron* **1990**, *46*, 2773-2788.
5. (a) Muratake, H.; Okabe, K.; Natsume, M. *Tetrahedron Lett.* **1988**, *29*, 6267-6270. (b) Okabe, K., Muratake, H.; Natsume, M. *Chem. Pharm. Bull.* **1989**, *37*, 563-564.
- 6 Nakatsuka, S., Masuda, T.; Goto, T. *Tetrahedron Lett.* **1987**, *28*, 3671-3674.
- 7 This bromide was already reported. Muntyan, G. E., Vaskan, R. N. *Izv Akad Nauk Mold SSR, Ser Biol Khim. Nauk* **1978**, 65-70 [*Chem. Abstr.* **1978**, *89*, 75405g] Actually the product was an inseparable ca. 1:1 mixture of **14** and 3,6,7-trimethyl-1,6-octadien-3-yl bromide. Using this mixture, the Grignard reaction product **16** was obtained only in a poor yield.
- 8 Saucy, G., Marbet, R. *Helv Chim Acta* **1967**, *50*, 2091-2095
- 9 Part 1: Muratake, H.; Natsume, M. *Tetrahedron* preceding paper.
- 10 Scheibye, S.; Pedersen, B. S.; Lawesson, S. O. *Bull Soc Chim. Belg.* **1978**, *87*, 229-238.
- 11 (a) Takashima, M., Sakai, H., Arima, K. *Agric Biol Chem* **1962**, *26*, 660-668. (b) Takashima, M., Sakai, H., Mori, R.; Arima, K. *Agric Biol Chem.* **1962**, *26*, 669-678 (c) Harada, H.; Nakata, H.; Hirata, Y. *Nippon Kagaku Zasshi* **1966**, *87*, 86-92
- 12 See the description in Part 1⁹
- 13 Fujiki, H.; Mori, M., Nakayasu, M., Terada, M., Sugimura, T. *Biochem Biophys Res Commun.* **1979**, *90*, 976-983
- 14 Gilchrist, T. L.; Lingham, D. A.; Roberts, T. G. *J Chem Soc, Chem Commun.* **1979**, 1089-1090
- 15 Hamada, Y.; Shioiri, T. *Chem Pharm Bull.* **1982**, *30*, 1921-1924.
16. Shioiri, T.; Ninomiya, K., Yamada, S. -1. *J Am Chem Soc.* **1972**, *94*, 6203-6205
- 17 Irie, K.; Hagiwara, N.; Funaki, A., Hayashi, H., Arai, M., Koshimizu, K. *Agric Biol Chem.* **1987**, *51*, 1733-1735
- 18 Yamada, S. -1.; Kasai, Y.; Shioiri, T. *Tetrahedron Lett* **1973**, 1595-1598
- 19 Okabe, K.; Muratake, H., Natsume, M. *Tetrahedron* **1990**, *46*, 5113-5120